Kimball Electronics reported first quarter 2027 results featuring a return to top-line growth, though earnings fell short of analyst expectations. While net sales of $390.8 million exceeded estimates by 5%, adjusted diluted EPS of $0.25 lagged behind the projected $0.33. Performance was bolstered by the Helvoet acquisition and strong medical vertical demand, leading management to reiterate full-year sales guidance at the high end of the range.
Key Highlights
- Net sales increased 7% year-over-year to $390.8 million, supported by 3% organic growth and an $12.4 million contribution from the Helvoet acquisition.
- The Medical vertical was the primary growth driver, with total sales increasing 14% and organic sales rising 9% compared to the prior year.
- Adjusted operating margin reached 4.3%, though GAAP results were impacted by $2.0 million in acquisition costs and $0.4 million in restructuring charges.
- Working capital efficiency remained steady with Cash Conversion Days at 82, matching the multiyear low achieved in the previous quarter.